WO2006001954A3 - Methods for promoting the formation of platelets and for treating blood and bone marrow disorders - Google Patents

Methods for promoting the formation of platelets and for treating blood and bone marrow disorders Download PDF

Info

Publication number
WO2006001954A3
WO2006001954A3 PCT/US2005/017735 US2005017735W WO2006001954A3 WO 2006001954 A3 WO2006001954 A3 WO 2006001954A3 US 2005017735 W US2005017735 W US 2005017735W WO 2006001954 A3 WO2006001954 A3 WO 2006001954A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
bone marrow
promoting
platelets
treating blood
Prior art date
Application number
PCT/US2005/017735
Other languages
French (fr)
Other versions
WO2006001954A2 (en
Inventor
Jonathan G Drachman
Brian J Lannutti
Manish Gandhi
Original Assignee
Puget Sound Blood Ct And Progr
Jonathan G Drachman
Brian J Lannutti
Manish Gandhi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US57344704P priority Critical
Priority to US60/573,447 priority
Priority to US62040204P priority
Priority to US60/620,402 priority
Application filed by Puget Sound Blood Ct And Progr, Jonathan G Drachman, Brian J Lannutti, Manish Gandhi filed Critical Puget Sound Blood Ct And Progr
Publication of WO2006001954A2 publication Critical patent/WO2006001954A2/en
Publication of WO2006001954A3 publication Critical patent/WO2006001954A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol

Abstract

The invention provides methods for promoting the differentiation of megakaryocytes, methods for forming platelets, and methods for reducing the number of abnormal or malignant cells in bone marrow. In some embodiments, the methods comprise the step of contacting megakaryocyte progenitors with an amount of a 3-(cyclohexanoheteroarylidenyl)-2-indolinone compound effective to promote their differentiation. In some embodiments, the 3-(cyclohexanoheteroarylidenyl)-2-indolinone compound is 2-oxo-3-(4, 5, 6, 7-tetrahydro-lH-indol-2-ylmethylene)-2,3-dihydro-lH-indole-5-sulfonic acid dimethylamide (SU6656). The invention also provides methods for treating blood and bone marrow disorders.
PCT/US2005/017735 2004-05-20 2005-05-20 Methods for promoting the formation of platelets and for treating blood and bone marrow disorders WO2006001954A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US57344704P true 2004-05-20 2004-05-20
US60/573,447 2004-05-20
US62040204P true 2004-10-19 2004-10-19
US60/620,402 2004-10-19

Publications (2)

Publication Number Publication Date
WO2006001954A2 WO2006001954A2 (en) 2006-01-05
WO2006001954A3 true WO2006001954A3 (en) 2006-03-23

Family

ID=35170037

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/017735 WO2006001954A2 (en) 2004-05-20 2005-05-20 Methods for promoting the formation of platelets and for treating blood and bone marrow disorders

Country Status (1)

Country Link
WO (1) WO2006001954A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008033030A1 (en) 2007-08-20 2009-02-26 Luk Lamellen Und Kupplungsbau Beteiligungs Kg A clutch unit
US8933071B2 (en) 2008-11-07 2015-01-13 Northwestern University Dimethyl fasudil for inducing polyploidization of megakaryocytes and for treating blood and bone marrow diseases and disorders
US7897602B2 (en) 2009-01-12 2011-03-01 Development Center For Biotechnology Indolinone compounds as kinase inhibitors
WO2014100636A2 (en) 2012-12-20 2014-06-26 The Trustees Of Columbia University In The City Of New York Methods of treating atherosclerosis or myeloproliferative neoplasms by administering a lyn kinase activator
WO2014100779A1 (en) 2012-12-21 2014-06-26 Advanced Cell Technology, Inc. Methods ofr production of platelets from pluripotent stem cells and compositions thereof
CN105308452B (en) 2013-01-03 2018-02-06 布里格姆女子医院有限公司 Fluid handling system and method of the biomimetic
US20160067301A1 (en) * 2013-04-12 2016-03-10 The Trustees Of Columbia University In The City Of New York Antagonism of abcg4, lyn kinase, and c-cbl e3 ligase to increase platelet count as therapy for thrombocytopenia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045689A2 (en) * 1999-12-22 2001-06-28 Sugen, Inc. Indolinone derivatives for modulation of c-kit tyrosine protein kinase
US20040052762A1 (en) * 2001-09-10 2004-03-18 Hua Yu Stat3 agonists and antagonists and therapeutic uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045689A2 (en) * 1999-12-22 2001-06-28 Sugen, Inc. Indolinone derivatives for modulation of c-kit tyrosine protein kinase
US20040052762A1 (en) * 2001-09-10 2004-03-18 Hua Yu Stat3 agonists and antagonists and therapeutic uses thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BLAKE R A ET AL: "SU6656, a Selective Src Family Kinase Inhibitor, Used To Probe Growth Factor Signaling", MOLECULAR AND CELLULAR BIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, US, vol. 20, no. 23, December 2000 (2000-12-01), pages 9018 - 9027, XP002989060, ISSN: 0270-7306 *
BROOME MARTIN A ET AL: "Selective Src family kinase inhibitors as potential therapeutic agents for cancer", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 42, March 2001 (2001-03-01), & 92ND ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; NEW ORLEANS, LA, USA; MARCH 24-28, 2001, pages 836, XP008059117, ISSN: 0197-016X *
DUEHRSEN U ET AL: "EFFECTS OF VASCULAR ENDOTHELIAL AND PLATELET-DERIVED GROWTH FACTOR RECEPTOR INHIIBITORS ON LONG-TERM CULTURES FROM NORMAL HUMAN BONE MARROW", GROWTH FACTORS, HARWOOD ACADEMIC PUBLISHERS GMBH, vol. 19, no. 1, 2001, pages 1 - 17, XP009020567, ISSN: 0897-7194 *
LANNUTTI BRIAN J ET AL: "Induction of polyploidization in leukemic cell lines and primary bone marrow by Src kinase inhibitor SU6656.", BLOOD, vol. 104, no. 11, Part 1, November 2004 (2004-11-01), & 46TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 04 -07, 2004, pages 797A - 798A, XP008059064, ISSN: 0006-4971 *
LANNUTTI BRIAN J ET AL: "Induction of polyploidization in leukemic cell lines and primary bone marrow by Src kinase inhibitor SU6656.", BLOOD. 15 MAY 2005, vol. 105, no. 10, 15 May 2005 (2005-05-15), pages 3875 - 3878, XP008059078, ISSN: 0006-4971 *
LANNUTTI BRIAN J ET AL: "Lyn tyrosine kinase regulates thrombopoietin-induced proliferation of hematopoietic cell lines and primary megakaryocytic progenitors", BLOOD, vol. 103, no. 10, 15 May 2004 (2004-05-15), pages 3736 - 3743, XP008059096, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
WO2006001954A2 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
Lu et al. Neural representations of temporally asymmetric stimuli in the auditory cortex of awake primates
Sharma et al. A sensitive period for the development of the central auditory system in children with cochlear implants: implications for age of implantation
Rholes et al. Adult attachment: Theory, research, and clinical implications.
Heil Auditory cortical onset responses revisited. I. First-spike timing
Ingram et al. Cognitive vulnerability to depression.
ES2364328T3 (en) Pyrimidine compound and medicinal composition thereof.
Saunders et al. Threshold, comfortable level and impedance changes as a function of electrode-modiolar distance
Benazzouz et al. Intraoperative microrecordings of the subthalamic nucleus in Parkinson's disease
Vandana et al. Thickness of gingiva in association with age, gender and dental arch location
Bjarnason et al. Circadian expression of clock genes in human oral mucosa and skin: association with specific cell-cycle phases
Puig et al. Serotonin modulates fast-spiking interneuron and synchronous activity in the rat prefrontal cortex through 5-HT1A and 5-HT2A receptors
Edeline et al. Diversity of receptive field changes in auditory cortex during natural sleep
Tonetti et al. Comparison of two different actigraphs with polysomnography in healthy young subjects
Cuffel Prevalence estimates of substance abuse in schizophrenia and their correlates.
Sverzut et al. The influence of tobacco on early dental implant failure
EP2253706A3 (en) Antisense modulation of kinesin-like 1 expression
NZ505844A (en) Inhibition of raf kinase using substituted heterocyclic ureas
HK1107641A1 (en) Piperidine- and piperazine-1-carboxylic acid amide derivatives and related compounds as modulators of fatty acid amide hydrolase (faah) for the treatment of anxiety, pain and other conditions (faah)- 1-
IL133007D0 (en) Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
EA007868B1 (en) Novel multicyclic compounds and the use thereof
WO2004048526A3 (en) MODULATION OF HIF1α AND HIF2α EXPRESSION
WO2005005599A3 (en) Modulation of c-reactive protein expression
MY155425A (en) Process for preparing amino crotonyl compounds
WO2001047935A2 (en) Novel bisamidate phosphonate prodrugs
MXPA06012059A (en) New pharmaceutical compositions for the treatment of sexual disorders ii.

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase in:

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase